NFKB1 and lung adenocarcinoma: Bortezomib treatment blocked the constitutive and inducible NF-κB activation of mouse lung adenocarcinoma, leading to suppressed MPE-related inflammation, angiogenesis, and vascular leakiness, and hence providing for a microenvironment less permissive for MPE development [9-15].